Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
about
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyPI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemiaA review of connectivity map and computational approaches in pharmacogenomics.The evolution of clinical trials for infant acute lymphoblastic leukemia.Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
P2860
Q28076097-32CA2754-FDBB-4FC6-94E5-D96DBE6C2D27Q35955221-532C25FD-C484-4146-A061-953933918786Q36244997-87262EF5-A914-4DD0-8794-F53073D594ECQ37730023-B61E13BA-1B6A-499C-9B2A-39DF4A9AC311Q38785283-627AEB91-23E8-4977-9043-F07E90D47D1AQ41320019-E25FB835-C6AD-4441-9ECC-6E8715A5F939Q41837321-79EC0D25-8792-4E5E-BEB0-162F9A98E551Q42314704-BA35D33E-6AD8-4E9E-934D-0998A20889E8Q47754054-9F0C645A-502C-4B35-9E2C-7967B89ADA05Q48090552-0B8DACB1-EBE3-4E43-B728-1525686480D0Q50854409-EDCECE25-6725-4978-BEBA-58D80D633293Q53763092-DA984C68-A80D-4EBA-B460-FDCC81B6697A
P2860
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@en
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@nl
type
label
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@en
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@nl
prefLabel
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@en
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@nl
P2093
P2860
P356
P1433
P1476
Chemical genomic screening ide ...... in MLL-rearranged infant ALL.
@en
P2093
J A P Spijkers-Hagelstein
P Schneider
S S Pinhanços
P2860
P2888
P304
P356
10.1038/LEU.2013.245
P577
2013-08-20T00:00:00Z
P6179
1026911334